Potential interaction between warfarin and high dietary protein intake

被引:11
作者
Hornsby, Lori B. [1 ]
Hester, E. Kelly [1 ]
Donaldson, Amy R. [1 ]
机构
[1] Montgomery Family Med REsidency Program, Montgomery, AL 36116 USA
来源
PHARMACOTHERAPY | 2008年 / 28卷 / 04期
关键词
high-protein diet; low-carbohydrate diet; warfarin; dietary effects; anticoagulation; drug-diet interaction; international normalized ratio;
D O I
10.1592/phco.28.4.536
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A 55-year-old Caucasian man was receiving warfarin therapy after undergoing aortic valve replacement. His international normalized ratio (INR) was stabilized with warfarin 95 mg/week for 5 weeks. Commencement of a low-carbohydrate, high-protein diet resulted in a series of subtherapeutic INRs that led to a 16% increase in the dosage requirement to maintain therapeutic INRs. After the patient discontinued the diet, his INR increased, and several dosage reductions were required until his INR stabilized with his original dosage of 95 mg/week. Two additional case reports have described a possible interaction between warfarin and a high-protein diet. The potential for increased dietary protein intake to raise serum albumin levels and/or cytochrome P450 activity has been postulated as mechanisms for the resulting decrease in INRs. Given the available animal and human data that demonstrate alterations in drug metabolism in the presence of altered dietary protein intake, an increase in warfarin metabolism due to cytochrome P450 activation appears to be the most likely cause. In addition to the previously reported cases, this case indicates a potential interaction between warfarin and a high-protein diet. Because of the popularity of high-protein diets and because of the risks associated with inadequate or excessive warfarin anticoagulation, patients and health care providers should be aware of this interaction to ensure appropriate monitoring when warranted.
引用
收藏
页码:536 / 539
页数:4
相关论文
共 10 条
[1]  
ANDERSON KE, 1991, ANNU REV NUTR, V11, P141, DOI 10.1146/annurev.nu.11.070191.001041
[2]   Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets [J].
Beatty, SJ ;
Mehta, BH ;
Rodis, JL .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) :744-747
[3]   Modulation of rat liver citochrome P450 by protein restriction assessed by biochemical and bacterial mutagenicity methods [J].
Cancino-Badías, L ;
Reyes, RE ;
Nosti, R ;
Pérez, I ;
Dorado, V ;
Caballero, S ;
Soria, A ;
Camacho-Carranza, R ;
Escobar, D ;
Espinosa-Aguirre, JJ .
MUTAGENESIS, 2003, 18 (01) :95-100
[4]   INCREASED CLEARANCE OF PROPRANOLOL AND THEOPHYLLINE BY HIGH-PROTEIN COMPARED WITH HIGH-CARBOHYDRATE DIET [J].
FAGAN, TC ;
WALLE, T ;
OEXMANN, MJ ;
WALLE, UK ;
BAI, SA ;
GAFFNEY, TE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (04) :402-406
[5]   EFFECTS OF HIGH PROTEIN, HIGH-CARBOHYDRATE, AND HIGH-FAT DIETS ON LABORATORY PARAMETERS [J].
FAGAN, TC ;
OEXMANN, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1987, 6 (04) :333-343
[6]   INTERACTION BETWEEN NUTRITION AND THEOPHYLLINE METABOLISM IN CHILDREN [J].
FELDMAN, CH ;
HUTCHINSON, VE ;
SHER, TH ;
FELDMAN, BR ;
DAVIS, WJ .
THERAPEUTIC DRUG MONITORING, 1982, 4 (01) :69-76
[7]   Pharmacokinetic changes in drugs during protein-calorie malnutrition: Correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes [J].
Lee, JH ;
Suh, OK ;
Lee, MG .
ARCHIVES OF PHARMACAL RESEARCH, 2004, 27 (07) :693-712
[8]   Comment: decreased warfarin effect after initiation of high-protein, low-carbohydrate diets - Reply [J].
Rodis, JL ;
Beatty, SJ ;
Mehta, BH .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (7-8) :1372-1372
[9]   Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not [J].
Schwabedissen, Cordula Meyer zu ;
Mevissen, Vera ;
Schmitz, Fabian ;
Woodruff, Seth ;
Langebartels, Georg ;
Rau, Thomas ;
Zerres, Klaus ;
Hoffmann, Rainer ;
Ortlepp, Jan R. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (09) :713-720
[10]   Pharmacogenetics of warfarin elimination and its clinical implications [J].
Takahashi, H ;
Echizen, H .
CLINICAL PHARMACOKINETICS, 2001, 40 (08) :587-603